Literature DB >> 33632278

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers.

Saghi Nooraei1, Howra Bahrulolum1, Zakieh Sadat Hoseini1, Camellia Katalani2, Abbas Hajizade3, Andrew J Easton4, Gholamreza Ahmadian5.   

Abstract

Virus-like particles (VLPs) are virus-derived structures made up of one or more different molecules with the ability to self-assemble, mimicking the form and size of a virus particle but lacking the genetic material so they are not capable of infecting the host cell. Expression and self-assembly of the viral structural proteins can take place in various living or cell-free expression systems after which the viral structures can be assembled and reconstructed. VLPs are gaining in popularity in the field of preventive medicine and to date, a wide range of VLP-based candidate vaccines have been developed for immunization against various infectious agents, the latest of which is the vaccine against SARS-CoV-2, the efficacy of which is being evaluated. VLPs are highly immunogenic and are able to elicit both the antibody- and cell-mediated immune responses by pathways different from those elicited by conventional inactivated viral vaccines. However, there are still many challenges to this surface display system that need to be addressed in the future. VLPs that are classified as subunit vaccines are subdivided into enveloped and non- enveloped subtypes both of which are discussed in this review article. VLPs have also recently received attention for their successful applications in targeted drug delivery and for use in gene therapy. The development of more effective and targeted forms of VLP by modification of the surface of the particles in such a way that they can be introduced into specific cells or tissues or increase their half-life in the host is likely to expand their use in the future. Recent advances in the production and fabrication of VLPs including the exploration of different types of expression systems for their development, as well as their applications as vaccines in the prevention of infectious diseases and cancers resulting from their interaction with, and mechanism of activation of, the humoral and cellular immune systems are discussed in this review.

Entities:  

Keywords:  Cancer vaccine; Expression and purification platforms; Immune response; Infectious disease vaccine; Subunit vaccine; Virus-like particles (VLPs)

Mesh:

Substances:

Year:  2021        PMID: 33632278      PMCID: PMC7905985          DOI: 10.1186/s12951-021-00806-7

Source DB:  PubMed          Journal:  J Nanobiotechnology        ISSN: 1477-3155            Impact factor:   10.435


  213 in total

1.  Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway.

Authors:  Stephanie J Win; Vernon K Ward; P Rod Dunbar; Sarah L Young; Margaret A Baird
Journal:  Immunol Cell Biol       Date:  2011-01-11       Impact factor: 5.126

2.  Particles associated with Australia antigen in the sera of patients with leukaemia, Down's Syndrome and hepatitis.

Authors:  M E Bayer; B S Blumberg; B Werner
Journal:  Nature       Date:  1968-06-15       Impact factor: 49.962

Review 3.  Use of plant viruses and virus-like particles for the creation of novel vaccines.

Authors:  Ina Balke; Andris Zeltins
Journal:  Adv Drug Deliv Rev       Date:  2018-08-30       Impact factor: 15.470

4.  Cowpea Mosaic Virus Nanoparticles and Empty Virus-Like Particles Show Distinct but Overlapping Immunostimulatory Properties.

Authors:  Chao Wang; Veronique Beiss; Nicole F Steinmetz
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

Review 5.  Non-viraemic transmission of tick-borne viruses.

Authors:  S Havlíková; M Ličková; B Klempa
Journal:  Acta Virol       Date:  2013       Impact factor: 1.162

6.  Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine.

Authors:  Johanna Marsian; Helen Fox; Mohammad W Bahar; Abhay Kotecha; Elizabeth E Fry; David I Stuart; Andrew J Macadam; David J Rowlands; George P Lomonossoff
Journal:  Nat Commun       Date:  2017-08-15       Impact factor: 14.919

Review 7.  Large-scale production and purification of VLP-based vaccines.

Authors:  Tiago Vicente; António Roldão; Cristina Peixoto; Manuel J T Carrondo; Paula M Alves
Journal:  J Invertebr Pathol       Date:  2011-07       Impact factor: 2.841

8.  A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.

Authors:  Ted M Ross; Kutub Mahmood; Corey J Crevar; Kirsten Schneider-Ohrum; Penny M Heaton; Rick A Bright
Journal:  PLoS One       Date:  2009-06-24       Impact factor: 3.240

Review 9.  The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B.

Authors:  Young Hee Joung; Se Hee Park; Ki-Beom Moon; Jae-Heung Jeon; Hye-Sun Cho; Hyun-Soon Kim
Journal:  Int J Mol Sci       Date:  2016-10-13       Impact factor: 5.923

10.  Engineering E. coli cell surface in order to develop a one-step purification method for recombinant proteins.

Authors:  Hamidreza Fasehee; Amin Rostami; Fatemeh Ramezani; Gholamreza Ahmadian
Journal:  AMB Express       Date:  2018-06-30       Impact factor: 3.298

View more
  56 in total

Review 1.  Toward rational vaccine engineering.

Authors:  Yashavantha L Vishweshwaraiah; Nikolay V Dokholyan
Journal:  Adv Drug Deliv Rev       Date:  2022-02-09       Impact factor: 15.470

Review 2.  Immunogenic cell stress and death.

Authors:  Guido Kroemer; Lorenzo Galluzzi; Claudia Galassi; Laurence Zitvogel
Journal:  Nat Immunol       Date:  2022-02-10       Impact factor: 25.606

3.  Human papilloma virus vaccine and VITT antibody induction.

Authors:  Adam J Kanack; Ingvild J Laegreid; Silje Johansen; Håkon Reikvam; Maria T Ahlen; Anand Padmanabhan
Journal:  Am J Hematol       Date:  2022-08-03       Impact factor: 13.265

Review 4.  Advances in Infectious Disease Vaccine Adjuvants.

Authors:  Jingyi Fan; Shengbin Jin; Lachlan Gilmartin; Istvan Toth; Waleed M Hussein; Rachel J Stephenson
Journal:  Vaccines (Basel)       Date:  2022-07-13

Review 5.  Vaccines against Major Poultry Viral Diseases: Strategies to Improve the Breadth and Protective Efficacy.

Authors:  Rajamanonmani Ravikumar; Janlin Chan; Mookkan Prabakaran
Journal:  Viruses       Date:  2022-05-31       Impact factor: 5.818

Review 6.  An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives.

Authors:  Alessio Facciolà; Giuseppa Visalli; Antonio Laganà; Angela Di Pietro
Journal:  Vaccines (Basel)       Date:  2022-05-22

7.  Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies.

Authors:  Anne-Cathrine S Vogt; Lukas Jörg; Byron Martina; Pascal S Krenger; Xinyue Chang; Andris Zeltins; Monique Vogel; Mona O Mohsen; Martin F Bachmann
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

8.  Peptide-guided JC polyomavirus-like particles specifically target bladder cancer cells for gene therapy.

Authors:  Wei-Hong Lai; Chiung-Yao Fang; Ming-Chieh Chou; Mien-Chun Lin; Cheng-Huang Shen; Chun-Nun Chao; Yeong-Chin Jou; Deching Chang; Meilin Wang
Journal:  Sci Rep       Date:  2021-06-04       Impact factor: 4.379

9.  Production of SARS-CoV-2 Virus-Like Particles in Insect Cells.

Authors:  Youjun Mi; Tao Xie; Bingdong Zhu; Jiying Tan; Xuefeng Li; Yanping Luo; Fei Li; Hongxia Niu; Jiangyuan Han; Wei Lv; Juan Wang
Journal:  Vaccines (Basel)       Date:  2021-05-26

Review 10.  A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics.

Authors:  Lauren Forchette; William Sebastian; Tuoen Liu
Journal:  Curr Med Sci       Date:  2021-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.